Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 2/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 14/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30429277 | 1.00 | SMARCA2 (0.44) | SMARCA2SMARCA4PBRM1RETCYP11B2 | |
| SCHEMBL25347928 | 0.89 | SMARCA2 (0.54) | SMARCA2SMARCA4PBRM1RETWNT1 | |
| SCHEMBL30520188 | 0.89 | SMARCA2 (0.54) | SMARCA2SMARCA4PBRM1RETWNT1 | |
| SCHEMBL25221239 | 0.88 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1CYP11B2WNT1 | |
| SCHEMBL30429245 | 0.87 | CYP11B2 (0.42) | RETCYP11B2ACVR1BTGFBR1 | |
| SCHEMBL25273169 | 0.87 | CYP11B2 (0.42) | RETCYP11B2ACVR1BTGFBR1 | |
| SCHEMBL30429285 | 0.83 | PGK1 (0.42) | RETPGK1WNT1GSK3BDYRK1A | |
| SCHEMBL25268453 | 0.83 | PGK1 (0.42) | RETPGK1WNT1GSK3BDYRK1A | |
| SCHEMBL25255621 | 0.81 | USP30 (0.43) | SMARCA2SMARCA4PBRM1CYP11B2WNT1 | |
| SCHEMBL29046333 | 0.80 | SMARCA2 (0.40) | SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| EP-4192835-A1 | 6-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Oncology Limited (IN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | SMARCC1, SMARCC2, SMARCA4 | SMARCA2 4/4885SMARCA4 3/4885PBRM1 19/4885 |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | SMARCC1, SMARCC2, SMARCA1 | SMARCA2 4/4885SMARCA4 6/4885PBRM1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.